12 Health Care Stocks Moving In Tuesday’s After-Market Session
Gainers
China SXT Pharmaceuticals (NASDAQ:SXTC) stock rose 10.9% to $0.6 during Tuesday's after-market session. The market value of their outstanding shares is at $9.2 million.
Conformis Receives FDA 510 Approval For Identity Imprint Cruciate Retaining Knee Replacement System
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K213389
Conformis Q3 EPS $(0.07) Misses $(0.06) Estimate, Sales $14.25M Miss $14.61M Estimate
Conformis (NASDAQ:CFMS) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.06) by 16.67 percent. This is a 22.22 percent increase over losses of $(0.09) per share from the
Earnings Scheduled For November 3, 2021
Companies Reporting Before The Bell
• R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion.
Conformis Posts Clinical Study Data For Its Knee Implants
Conformis Inc (NASDAQ:CFMS) announced results of a published retrospective study of procedures using Conformis’ patient-specific iTotal CR (cruciate-retaining) knee replacement…
Conformis, Inc. Announces Clinical Study Results for Its Personalized Knee Implants
Conformis, Inc. (NASDAQ:CFMS) announced today the strong results of a published retrospective study of procedures using Conformis' patient-specific iTotal® CR (cruciate-retaining) knee replacement implant,
Conformis Receives FDA 510K Approval For Identity Imprint Knee Replacement System
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K212411
Oppenheimer Maintains Outperform on Conformis, Lowers Price Target to $2.5
Oppenheimer analyst Steven Lichtman maintains Conformis (NASDAQ:CFMS) with a Outperform and lowers the price target from $3 to $2.5.
Investors React To Conformis’ Annual Sales Guidance Update
Conformis Inc (NASDAQ:CFMS) stock is down after the Q3 revenue update ahead of the Oppenheimer Fall Healthcare Life Sciences & MedTech…